97055 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Molecules with a "CD"-designation not provided for elsewhere
Sequence arrangements and sequences for neoepitope presentation
#902NUCLEIC ACIDS FOR TREATMENT OF PEANUT ALLERGIES
#903Methods and compositions for transducing lymphocytes and regulated expansion thereof
#904INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
#905Tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof
#906Non-human animals having a humanized signal-regulatory protein gene
#907Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#908Compositions and methods of stimulating and expanding T cells
#909Antigen-binding proteins comprising recombinant protein scaffolds
#910Compositions and methods for cartilage defect repair using a RHAMM-mimetic peptide
#911Targeted/TGF-ßRII fusion proteins and methods for making same
#912METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
#913Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
#914Enhanced production of immunoglobulins
#915PANCREATIC CANCER TARGETS AND USES THEREOF
#916Compositions, methods and kits for treating complement related disorders
#917Treating myelin diseases with optimized cell preparations
#918P97-IDS fusion proteins
#919Surrogates of post-translationally modified proteins and uses thereof
#920PSGL-1 modulators and uses thereof
#921Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
#922Breast and ovarian cancer vaccines
#923Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#924Chimeric inhibitor molecules of complement activation
#925Replication defective adenovirus vector in vaccination
#926Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#927Neutralizing antibodies and methods of use thereof
#928Constructs having a SIRP-α domain or variant thereof
#929Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
#930CD133 EPITOPES
#931Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
#932Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
#933Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
#934Lysosomal targeting of antigens employing nucleic acids encoding lysosomal membrane polypeptide/antigen chimeras
#935Syndecan peptides and polypeptides and uses thereof
#936Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#937Composition comprising branched multipeptide vaccine and vaccine comprising the same
#938Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#939Pathogen-resistant animals having modified CD163 genes
#940Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#941Method for evaluation of function of phagocyte
#942CSGP4 - Specific Chimeric Antigen Receptor for Cancer
#943Non-human animals having a humanized signal-regulatory protein gene
#944Colostrum/milk protein compositions
#945Methods and compositions for the inhibition of TRPV4
#946CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
#947RECURRENT FUSION GENES IDENTIFIED IN HIGH -GRADE SEROUS OVARIAN CARCINOMA
#948Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#949Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
#950Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules
#951SIRP polypeptide compositions and methods of use
#952Crystals of angiotensin-converting enzyme (ACE)
#953DRUG DELIVERY SYSTEM
#954Inhibitor targeting specific complement system, and preparation method and use thereof
#955Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#956NRG1 fusion genes in cancer
#957Multipartite signaling proteins and uses thereof
#958RECOMBINANT FACTOR VIII PROTEINS
#959METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
#960Methods for treating cancer
#961Anti-DR6 antibodies and methods of immune regulation
#962RNA transcription vector and uses thereof
#963Nucleic acids for treatment of allergies
#964Chloroplast expressing colostrum or milk polypeptides
#965Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins
#966Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#967Cyclic peptide conjugates and methods of use
#968ANTI-ENDOGLIN ANTIBODIES AND KNOCKIN MICE EXPRESSING NOVEL HUMAN/MOUSE CHIMERIC ENDOGLIN
#969Soluble CD33 for treating myelodysplastic syndromes (MDS)
#970Methods for increasing palatability of pet foodstuff
#971ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR ROR1
#972Compositions and methods for treatment of cancer
#973METHOD OF DIAGNOSING KIDNEY DAMAGE IN DIABETIC PATIENTS USING URINARY CD36 AS A BIOMARKER
#974Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#975Compositions and methods for treatment of cancer
#976Dipeptidyl peptidase-IV (DPPIV), inhibitory peptide compound, composition containing the same, and production method for the same
#977SIRP-α immunoglobulin fusion proteins
#978Method of treating cancer with an EGFR targeted immunomodulatory fusion protein
#979Regulatory T cell mediator proteins and uses thereof
#980Domain 5 of CD163 for use in antiviral compositions against PRRS, and transgenic animals
#981Compositions and methods for treatment of cancer
#982Non-human animals having a humanized cluster of differentiation 47 gene
#983Genetically modified mouse whose genome comprises a humanized CD274 gene
#9843-aryl propiolonitrile compounds for thiol labeling
#985Therapeutic delivery vesicles
#986Methods and systems for predicting misfolded protein epitopes
#987Compositions and methods for treatment of cancer
#988Canine Anti-CD20 Antibodies
#989Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency
#990Chicken cells for improved virus production
#991Method for producing natively folded proteins in a prokaryotic host
#992Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
#993Replication defective adenovirus vector in vaccination
#994Immunosuppressive TGF-β signal converter
#995Non-human animals having a humanized signal-regulatory protein gene
#996Method of reducing blood glucose by administering RON agonists
#997Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
#998Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
#999Compounds for treating neurodegenerative proteinopathies
#1000TLR8 TRANSGENIC ANIMALS
#1001Methods of modulating GABAergic inhibitory synapse formation and function
#1002SUBSTANCES AND METHODS FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY RELATED CONDITIONS OR DISEASES
#1003Compositions comprising soluble CD84 or anti-CD84 antibodies and methods for diagnosing and treating B-CLL
#1004Angiopoietin-2 specific TIE2 receptor
#1005Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
#1006PEPTIDIC ANTAGONISTS OF CLASS III SEMAPHORINS/NEUROPILINS COMPLEXES
#1007Endoglin polypeptides and uses thereof
#1008Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
#1009HUMANIZED TRANSGENIC SINGLE NUCLEOTIDE POLYMORPHISM ANIMAL SYSTEMS
#1010Immune receptor modifier conjugate and preparation method and use thereof, coupling precursor for preparing same, and compound for synthesizing coupling precursor
#1011PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING FUSION PROTEIN
#1012Peptides that stimulate subcutaneous adipogenesis
#1013Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor
#1014Multipartite signaling proteins and uses thereof
#1015Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
#1016Methods Of Producing A Secreted Protein
#1017Peptides that bind to epithelial cell adhesion molecule
#1018Methods of use of soluble CD24 for therapy of rheumatoid arthritis
#1019Syndecan peptides and polypeptides as inhibitors of cancer
#1020Syndecan peptides and polypeptides as inhibitors of cancer
#1021Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#1022Polypeptide hydrogels and uses related thereto
#1023DEGRANULATION INDICATOR AND METHODS OF USE THEREOF
#1024Variants of IgG Fc with limited amine groups
#1025CD31 peptides
#1026Combination for treating an inflammatory disorder
#1027Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1028Modulation of TLR4-signaling pathway
#1029Recombinant bacterium and uses thereof
#1030Dendrimer conjugates for coating cells
#1031Fermented infant formula with non digestible oligosaccharides
#1032Antimicrobial peptide and use thereof
#1033Method of diagnosing and treating infectious disseminated intravascular coagulation
#1034Anti-LAMP5 antibody and utilization thereof
#1035CD147 as receptor for pilus-mediated adhesion of to vascular endothelia
#1036NKP30 receptor targeted therapeutics
#1037Modification of CXCR4 using engineered zinc finger proteins
#1038Use of semaphorin-4D binding molecules for treatment of atherosclerosis
#1039Compositions for treatment of cancer
#1040Compositions for treatment of cancer
#1041Marker-suicide gene useful in adoptive cell therapy
#1042Non-human animals having a humanized signal-regulatory protein gene
#1043Non-human animals having a humanized signal-regulatory protein gene
#1044Protein inhibitors to complement and VEGF pathways and methods of use thereof
#1045HYBRID CONSTANT REGIONS
#1046COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR
#1047NOVEL FUSION GENES IDENTIFIED IN LUNG CANCER
#1048Transgenic immunodeficient mouse expressing human SIRP-alpha
#1049Toll-like receptor 2 binding epitope and binding member thereto
#1050Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
#1051Crystal
#1052Adenoviruses expressing heterologous tumor-associated antigens
#1053Mammalian Cell Culture System for Large-Scale Expression of Recombinant Proteins
#1054Neutralizing antibodies and methods of use thereof
#1055Targeted/immunomodulatory fusion proteins and methods for making same
#1056Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof
#1057METHOD FOR CULTURING CELLS IN ORDER TO PRODUCE SUBSTANCES
#1058Soluble endoglin and uses thereof
#1059Truncated CD20 protein, deltaCD20
#1060Anti-CD22 chimeric antigen receptors
#1061Semaphorin 7a Induced Lung Fibrogenesis Occurs in a CD-4-Dependent, Macrophage Dependent Manner
#1062CD20 CONFORMATIONAL ISOMERS AND METHODS OF USING
#1063CD123-specific chimeric antigen receptor redirected T cells and methods of their use
#1064Indirect antigen-specific T cell recognition assay
#1065Methods of using ERBB2 conjugate peptides
#1066Chimeric antigen receptor
#1067Antigen-binding proteins comprising recombinant protein scaffolds
#1068Soluble protein CD5 or CD6 for the treatment of cancer or tumor or for use as an adjuvant
#1069Prominin-1 peptide fragments and uses thereof
#1070SOLUBLE PROTEINS FOR USE AS THERAPEUTICS
#1071Peptides that stimulate subcutaneous adipogenesis
#1072CONSTITUTIVELY ACTIVE UPAR VARIANTS AND THEIR USE FOR THE GENERATION AND ISOLATION OF INHIBITORY ANTIBODIES
#1073Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#1074Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses
#1075Compositions comprising soluble CD84 or anti-CD84 antibodies and methods for diagnosing and treating B-CLL
#1076Cellular permissivity factor for viruses and uses thereof
#1077Peptides and methods using same
#1078Methods of use of soluble CD24 for therapy of rheumatoid arthritis
#1079Use of chimeric antigen receptor-modified T cells to treat cancer
#1080Anti-SEMA4D antibodies and epitopes
#1081Porcine reproductive and respiratory syndrome virus resistant animals
#1082Reducing soluble urokinase receptor in the circulation
#1083Targeting complement factor H for treatment of diseases
#1084Method of preparing antigen for acquiring anti-hydrophobic peptide antibody
#1085Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
#1086Regulatory T cell mediator proteins and uses thereof
#1087Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#1088Surrogates of post-translationally modified proteins and uses thereof
#1089MONOCLONAL ANTIBODIES
#1090METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES
#1091Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
#1092Novel Method of Isolation of TLR4 from Cell Lysates of Mononuclear Cells
#1093Chimeric vaccines
#1094Use of chimeric antigen receptor-modified T-cells to treat cancer
#1095Three-dimensional structure of complement receptor type 2 and uses thereof
#1096Virus like particle composition
#1097Glycated CD59 peptides, their preparation, and uses thereof
#1098Chimeric inhibitor molecules of complement activation
#1099COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING A PRECURSOR LESION AND/OR ESOPHAGEAL CANCER
#1100CD133 epitopes
#1101Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
#1102Compositions, kits and methods for treatment of complement-related disorders
#1103Therapeutic apyrase constructs, apyrase agents, and production methods
#1104Soluble endoglin and uses thereof
#1105Soluble tandem selectin glycoprotein ligand molecules
#1106Methods of use of soluble CD24 for therapy of rheumatoid arthritis
#1107ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS
#1108METHOD OF QUANTIFYING RECOVERY RATE OF EXOSOME
#1109Porcine CTLA-4 for xenograft-specific immunosuppression
#1110Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
#1111Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1112Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
#1113SOLUBLE PROTEINS FOR USE AS THERAPEUTICS
#1114METHODS OF EVALUATING RELAPSE RISK OF ACUTE MYELOID LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE
#1115Targeting the neuromuscular junction for treatment
#1116Antibody Mimetic Scaffolds
#1117Regulatory T cell mediator proteins and uses thereof
#1118METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS
#1119Treatment of renal disease
#1120Transgenic mice expressing human toll-like receptor 8
#1121Targeted particles and methods of using the same
#1122Hybrid and chimeric polypeptides that regulate activation of complement
#1123Method for producing natively folded proteins in a prokaryotic host
#1124Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
#1125Antigen-binding proteins comprising recombinant protein scaffolds
#1126Chimeric toll-like receptor/MD-2 polypeptides and methods of use thereof
#1127Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
#1128T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF
#1129Truncated CD20 protein, deltaCD20
#1130Pancreatic cancer targets and uses thereof
#1131Signature Of Secreted Protein Isoforms Specific To Ovarian Cancer
#1132Mass spectrometric methods and products
#1133CD109 POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF SKIN CELLS
#1134METHOD TO DEPLETE MONOCLONAL ANTIBODIES IN A BIOLOGICAL SAMPLE
#1135METHODS OF TREATING INFLAMMATION
#1136HEPATITIS C RECEPTOR PROTEIN CD81
#1137Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
#1138Complement receptor 1 and 2 fusion proteins
#1139COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS
#1140Cellular permissivity factor for viruses and uses thereof
#1141COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS
#1142Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
#1143NKG2D-fc for immunotherapy
#1144Blood group antigens of different types for diagnostic and therapeutic applications
#1145Composition and method for facilitating the internalization of a therapeutic agent into a cell
#1146MCP1-Ig fusion variants
#1147METHODS AND MATERIALS RELATING TO CD84-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES
#1148Methods for producing soluble membrane-spanning proteins
#1149Methods and compositions for diagnosing and treating diseases
#1150Method to block the infection by flaviviruses, molecules and uses
#1151CD5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin
#1152Prominin-1 peptide fragments and uses thereof
#1153Compositions comprising soluble CD84 or anti-CD84 antibodies and methods for diagnosing and treating B-CLL
#1154Immunogenic peptides
#1155Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
#1156Radioprotectants targeting thrombospondin-1 and CD47
#1157Chimeric vaccines
#1158ANIMALS WITH REDUCED BODY FAT AND INCREASED BONE DENSITY
#1159Antibodies against CD38 for treatment of multiple myeloma
#1160Canine anti-CD20 antibodies
#1161ATTRACTIN/MAHOGANY-LIKE POLYPEPTIDES, POLYNUCLEOTIDES, ANTIBODIES AND METHODS OF USE THEREOF
#1162Method for evaluation of function of phagocyte
#1163Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
#1164METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE
#1165Treating myelin diseases with optimized cell preparations
#1166Mass spectrometric methods and products
#1167METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE
#1168Baboon homolog of human CD147
#1169METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE
#1170METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE
#1171Covalent Factor VII-Tissue Factor Complex
#1172Diagnosis and treatment of autism using CD38
#1173Regulatory T cell mediator proteins and uses thereof
#1174SUBSTANCE FOR OBTAINING HIGHLY EFFECTIVE TUMOR MEDICATIONS AS WELL AS A PROCESS
#1175Antibodies for diagnosis and treatment of blood platelet alloimmune disorders
#1176Targeting complement factor H for treatment of diseases
#1177Method for the separation of cells
#1178CD14 AND PEPTIDES THEREOF FOR PROTECTION OF CELLS AGAINST CELL DEATH
#1179Methods of producing a secreted protein
#1180Methods for suppressing Toll-like Receptor 4 (TLR4) function using TLR14 antagonists
#1181Compositions and methods for treatment of angiogenesis in pathological lesions
#1182CD133 epitopes
#1183Recombinant ACE2 polypeptide dimer
#1184Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#1185Modification of CXCR4 using engineered zinc finger proteins
#1186METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS
#1187CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS
#1188Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
#1189DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR SUPERFAMILY MEMBERS
#1190COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
#1191Cellular permissivity factor for viruses and uses thereof
#1192Chimeric toll-like receptor/MD-2 polypeptides and methods of use thereof
#1193Crystal structure of CD147 extracellular region and use thereof
#1194Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
#1195CD47 related compositions and methods for treating immunological diseases and disorders
#1196MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
#1197Acute leukemia and lymphoblastic lymphona-specific CD43 epitope
#1198METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
#1199Peptidic antagonists of class III semaphorins/neuropilins complexes
#1200LAMININ BINDING SITE